"PATH-29. CLINICAL SIGNIFICANCE OF TEMOZOLOMIDE-INDUCED SOMATIC HYPERMUTATION IN INITIALLY LOW-GRADE IDH-MUTANT DIFFUSE GLIOMAS" by Yao Yu

Article

PATH-29. CLINICAL SIGNIFICANCE OF TEMOZOLOMIDE-INDUCED SOMATIC HYPERMUTATION IN INITIALLY LOW-GRADE IDH-MUTANT DIFFUSE GLIOMAS

Neuro-oncology (2018)

Yao Yu, University of California, San Francisco
Stephanie Hilz, University of California, San Francisco
Matthew Grimmer, University of California, San Francisco
David Solomon, University of California, San Francisco
Serah Choi, University of California, San Francisco
Michael Wahl, Samaritan Pastega Regional Cancer Center, Corvalis, CA, USA
Tali Mazor, Harvard University
Chibo Hong, University of California, San Francisco
Anny Shai, University of California, San Francisco
Joanna J Phillips, University of California, San Francisco
Javier Villanueva-Meyer, University of California, San Francisco
Michael McDermott, University of California, San Francisco
Daphne Haas-Kogan, Harvard University
Jennie Taylor, University of California, San Francisco
Nicholas Butowski, University of California, San Francisco
Jennifer Clarke, University of California, San Francisco
Mitchel Berger, University of California, San Francisco
Annette Molinaro, University of California, San Francisco
Susan Chang, University of California, San Francisco
Joseph Costello, University of California, San Francisco
Nancy Ann Oberheim Bush, University of California, San Francisco

Link

Disciplines

Publication Date

November 5, 2018

DOI

10.1093/NEUONC/NOY148.685

Citation Information

Yao Yu, Stephanie Hilz, Matthew Grimmer, David Solomon, et al.. "PATH-29. CLINICAL SIGNIFICANCE OF TEMOZOLOMIDE-INDUCED SOMATIC HYPERMUTATION IN INITIALLY LOW-GRADE IDH-MUTANT DIFFUSE GLIOMAS" Neuro-oncology Vol. 20 (2018)
Available at: http://works.bepress.com/michael-mcdermott/136/